Shigemasa C, Shirota K, Urabe K, Kouchi T, Mitani Y, Ueta Y, Yoshida A, Mashiba H
First Department of Internal Medicine, Tottori University School of Medicine, Yonago, Japan.
Horm Res. 1991;35(5):208-12. doi: 10.1159/000181904.
A 56-year-old man presented with clinical and biochemical hyperthyroidism with high thyroid 99mTc uptake, positive result for antimicrosomal antibody (MCHA; 1:8,100) and markedly high activities of thyrotropin-binding inhibitory immunoglobulin (TBII; 90.0%) and thyroid-stimulating antibody (TSAb; 2,400%). Fifty days after the initiation of antithyroid drug therapy, he developed a painful tender enlarged thyroid and an accelerated erythrocyte sedimentation rate (ESR), which were followed immediately by hypothyroidism with a transient increase in MCHA titer (peak; 1:218,700) despite of maintenance of high TBII and TSAb activities. Two and a half months after the recovery from hypothyroidism, recurrent hyperfunction was observed with further elevation of TSAb activity (4,643%). After about 2 weeks, recurrences of a painful tender enlarged thyroid and an accelerated ESR, which were followed by abrupt progression to hypothyroidism, were found. Specimens obtained when he had still slightly tender goiter after the first and second episodes of neck pain showed microscopically extremely extended interstitial fibrosis with collapsed follicles and moderate lymphocytic infiltration. Thyroid-stimulation-blocking antibody was not detected at either onset of hypothyroidism. Thus, it is possible that Graves' disease, subacute aggravation of chronic thyroiditis and hypothyroidism coexist in the same individual. In such patients, thyroid status may be determined by the degree of each of the stimulating factors (TSH, TSAb and/or unknown factors) and suppressive or destructive factors (humoral and/or cellular) and may be changed in a very short interval.
一名56岁男性出现临床和生化方面的甲状腺功能亢进,甲状腺99mTc摄取率高,抗微粒体抗体检测结果呈阳性(MCHA;1:8,100),促甲状腺素结合抑制性免疫球蛋白(TBII;90.0%)和促甲状腺素刺激抗体(TSAb;2,400%)活性显著升高。在开始抗甲状腺药物治疗50天后,他出现甲状腺疼痛性肿大且红细胞沉降率(ESR)加快,随后尽管TBII和TSAb活性维持在较高水平,但仍出现甲状腺功能减退,同时MCHA滴度短暂升高(峰值;1:218,700)。在从甲状腺功能减退恢复两个半月后,观察到复发的甲状腺功能亢进,TSAb活性进一步升高(4,643%)。约2周后,发现再次出现甲状腺疼痛性肿大和ESR加快,随后迅速进展为甲状腺功能减退。在他首次和第二次颈部疼痛后甲状腺仍有轻微压痛时获取的标本,显微镜检查显示间质纤维化极度扩展,滤泡塌陷,伴有中度淋巴细胞浸润。在甲状腺功能减退发作时均未检测到甲状腺刺激阻断抗体。因此,Graves病、慢性甲状腺炎亚急性加重和甲状腺功能减退可能在同一患者中共存。在这类患者中,甲状腺状态可能由各种刺激因素(促甲状腺激素、TSAb和/或未知因素)以及抑制或破坏因素(体液和/或细胞因素)的程度决定,且可能在很短时间内发生变化。